Clinical Trial ECOG 2511
- Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
- Principal Investigator
- Melissa Johnson
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.ECOG 2511
- The purpose of this study is to compare the effects, good and/or bad, of veliparib when combined with the standard commonly-used drugs (cisplatin and etoposide) on patients and their lung cancer.
- This study is for patients who have small cell lung cancer and have not had prior treatment for their cancer. In this study an investigational drug (veliparib) or a placebo (dummy pill) will be given in addition to cisplatin and etoposide. Investigational means that the drug is currently being tested and is not approved for sale in the United States by the Food and Drug Administration (FDA). Cisplatin and etoposide were chosen for this trial because the benefits and risks are well known, and because together they are currently the most effective therapies against small cell lung cancer.
Some of the eligibility criteria include:
- Participants must have small cell lung cancer.
- Participants cannot have had prior chemotherapy or biologic therapy for small cell lung cancer.
- Participants must be 18 or older.
- Description of Treatment
- Participants will be "randomized" to get either veliparib or placebo. Randomization means participants will be randomly assigned to a treatment based on chance, like a flip of a coin. This is a double-blinded study, which means that neither the participant or the study doctor or the study staff will know which treatment each participant is receiving. In addition to the study drug/placebo, participants in both groups will get cisplatin and etoposide as the standard chemotherapy for small cell lung cancer. Both cisplatin and etoposide will be given by vein (IV). The chemotherapy will be given in 3 week cycles. A total of 4 cycles will be given.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Melissa Johnson
- A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer
- Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 5 - LDE225 for patients with PTCH1 and SMO mutated tumors
- Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFC600 Mutated Tumors
- Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors Local
- A Phase IB Open-Label, Multi-Center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYl719 in Adult Patients with Selected Advanced Solid Tumors
- Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, CKIT, FLT3, CSFR1, TRK and RET
- A Phase II, Multicenter, Single-Arm Study of MPDL3280a in Patients with PD-L1–Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
last updated: 17-Sep-14 04:34 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.